Fermenta Board Approves Sale of Environmental Solutions Business to Wholly Owned Subsidiary

▴ Fermenta Biotech Limited
To enable specialized management and accelerated growth of environmental business vertical that includes waste management, water treatment, and bioremediation
Mumbai, 19 September 2025: Fermenta Biotech Limited, India's leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes for the global markets, today announced that its Board of Directors has approved the sale of its environmental solutions business operations to a wholly owned subsidiary, Fermenta Environment Solutions Private Limited (FESPL) on a slump sale basis. This strategic business transfer, effective 1 October 2025, represents another important milestone in Fermenta's commitment to sustainable innovation and environmental stewardship and enhances operational focus both at parent and subsidiary level. Following this transfer the subsidiary will continue and expand the business of conceiving, designing, providing, and manufacturing for sale and distribution a wide range of environmental solutions. The subsidiary's comprehensive portfolio will include—but not be limited to—solid waste management, wastewater and water management, lake and pond bioremediation, fly ash handling, ground and soil remediation, oil sludge treatment, and air pollution management. Additionally, the entity will undertake the installation, operation, and maintenance of sewage treatment plants (STPs), water treatment plants (WTPs), and effluent treatment plants (ETPs), either independently or through strategic collaborations. This strategic move integrates scientific capability with sustainable development, positioning FESPL to address one of the most pressing challenges of our time—environmental resilience. The initiative also aligns with Fermenta’s vision to leverage its expertise and capabilities to create solutions that benefit both business and society. Comment from Prashant Nagre - Managing Director "The Board's approval for this slump sale transaction marks a significant step in our journey toward comprehensive sustainability leadership. By transferring our environmental solutions portfolio to a dedicated subsidiary, we are creating a focused entity that can accelerate growth and innovation in this critical sector. This structured approach will enable specialized management, enhanced operational efficiency, and targeted resource allocation at both parent and subsidiary levels. The transaction reflects Fermenta’s commitment to applying our decades-honed capabilities to address critical environmental challenges while creating long-term value for all stakeholders. This strategic move perfectly complements our core business and reinforces our strategy of sustainable innovation that benefits both business and society." About Fermenta Biotech Limited (www.fermentabiotech.com) delivers best-in-class, science-validated nutritional ingredients across pharmaceuticals, dietary supplements, food & beverage, veterinary, and animal nutrition industries. Our state-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh), Dahej (Gujarat), and Tirupati (Andhra Pradesh), supported by the R&D Excellence Centre at Thane (near Mumbai) drive Fermenta's comprehensive portfolio of premium vitamins, nutritional premixes and ingredients that exceed the unique needs and stringent regulatory standards of over 400 discerning customers in more than 60 countries. With decades of expertise at global-scale complex manufacturing, Fermenta also provide research-based custom solutions in green chemistry, APIs & intermediates, and environmental solutions. Safe Harbour Statement Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, market opportunities, competitive positioning, slump sale transaction potential, the progress and results of research and development, potential project characteristics, project potential, and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements due to various factors including market conditions, regulatory changes, competitive dynamics, and other business risks. Fermenta Biotech Limited assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions, or other factors, except as and when required by applicable law.
Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Healthcare Trends in 2026: What India's Doctors, Hospitals, and Patients Need to KnowJuly 18, 2026
Monsoon Health Problems in India: Understanding the Risks, Symptoms, and PreventionJuly 18, 2026
Fortis Escorts Faridabad Launches Faridabad’s First Comprehensive Lung Failure Clinic for Advanced Respiratory and Transplant CareJuly 17, 2026
What Seemed Like Persistent Gas Turned Out To Be A 30-cm Rare Cancer Occupying Most Of Her AbdomenJuly 17, 2026
Kidney Stone Prevention Initiative Unites More Than 8,200 Doctors Across India, Earns Asia Book of Records RecognitionJuly 17, 2026
Moscow radiologists introduce AI tool for hip dysplasia diagnosisJuly 17, 2026
Sharrp Ventures leads 100 CR investment in Naturis Cosmetics’ first institutional funding roundJuly 17, 2026
Eugenix Challenges Hair Loss Stigma With Nationwide 'I Chose Transformation' Campaign Featuring Boney KapoorJuly 17, 2026
How Artificial Intelligence is Reshaping Preventive Healthcare Through Earlier Detection and Smarter Clinical InsightsJuly 17, 2026
Five Common Myths About Children's Urinary Problems That Parents Should Stop BelievingJuly 17, 2026
Robotics in Surgery: How Robot-Assisted Procedures Are Transforming Healthcare in IndiaJuly 17, 2026
Wearable Health Devices: How Smart Technology Is Changing Healthcare in IndiaJuly 17, 2026
Sankara Eye Hospitals Successfully Hosts 20th Annual VISION 2020 India Conference, Celebrating 50 Years of the Sankara MovementJuly 16, 2026
Manipal Hospital Bhubaneswar Successfully Treats Rare Brain Injury Caused by Post-Traumatic Workplace AccidentJuly 16, 2026
Immuneel Therapeutics and Tata Memorial Centre Sign Strategic MoU to Advance Cell and Gene Therapy Research in India July 16, 2026
Breast Cancer Early Warning Signs: What Every Woman in India Needs to KnowJuly 16, 2026
HbA1c Test Explained: What It Measures, Normal Range, and Why It Matters for IndiansJuly 16, 2026
Not Just Weight Loss: How Bariatric Surgery Improves Diabetes, PCOS, and Thyroid-Related Health ChallengesJuly 15, 2026
Leiutis Pharmaceuticals announces CDSCO approval for Global-First Synthetic CBD Therapy for Mild to Moderate Anxiety DisordersJuly 15, 2026
Dr Agarwals Institute of Optometry and SASTRA University Jointly Launch Optometry ProgrammeJuly 15, 2026